ALPHARETTA, Ga., Nov. 12, 2014 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV) today reported financial results for the three and nine months ended September 30, 2014 and provided a business update. The Company will host a conference call on Thursday, November 13, 2014, at 10:00 a.m. Eastern Time.
Revenue increased 53% for the quarter ended September 30, 2014, as compared to the same period in 2013, and 20% year-to-date through higher sales of devices and related applicators."In addition to the growth we saw in the third quarter from sales in South Korea over our recurring sales in Europe, we are continuing to work to find additional distribution partners to expand sales of our CE Marked devices in other areas such as the GCC region which includes Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman," commented Kevin A. Richardson, II, Chairman of the board of directors.
The Company has enrolled 126 patients in the Phase III supplemental clinical trial using dermaPACE® for treating diabetic foot ulcers. The Company expects to enroll the necessary 130 patients for the second independent Data Monitoring Committee (DMC) efficacy analysis in November 2014 and suspend enrollment at that time until receiving DMC feedback in Q1-2015. "We remain focused on completing the dermaPACE clinical trial as soon as possible to address this $3 billion market opportunity in the United States," stated Mr. Richardson.
The Company began clinical work at several leading universities for the use of the Company's patented technology in biofilm destruction, blood sterilization and stem cell proliferation. In addition, the Company established an off-site testing facility and started testing a small scale water treatment system for the non-medical use of the Company's patented technology for cleaning industrial waters. "Our technology platform includes 38 issued and pending patents, and finding additional strategic partners to help us monetize and advance new uses for our technology covered by these patents into other verticals and applications, including non-medical uses such as cleaning industrial waters, is very important for us to achieve our ultimate goal, which is to maximize shareholder value," concluded Mr. Richardson.
Third Quarter Financial Results
Revenue for the three months ended September 30, 2014 was $227,492, compared to $148,421 for the same period in 2013, an increase of $79,071, or 53%. The increase in revenue for 2014 was due to higher sales of orthoPACE devices in 2014 in Asia/Pacific, as compared to the prior year, as well as higher sales of refurbished applicators in Europe.
Research and development expenses for the three months ended September 30, 2014 were $708,304, compared to $775,717 for the same period in 2013, a decrease of $67,413, or 9%. Research and development expenses decreased in 2014 as a result of higher costs for third parties used in the dermaPACE clinical study in 2013 at the start of the more costly enrollment phase in June 2013.
General and administrative expenses for the three months ended September 30, 2014 were $780,115, as compared to $1,151,709 for the same period in 2013, a decrease of $371,594, or 32%. The decrease in general and administrative expenses is primarily due to reduced stock-based compensation expense for 2014 due to the forfeiture of non-vested stock options by terminated employees and reduced financial related consulting expenses with the completion of the private placement in March 2014.
Net loss for the three months ended September 30, 2014 was $1,492,905, or ($0.03) per basic and diluted share, compared to a net loss of $4,436,790, or ($0.14) per basic and diluted share, for the same period in 2013, a decrease in the net loss of $2,943,885, or 66%. The decrease in the net loss for 2014 was primarily a result of the non-cash other expenses of $2,459,445 in 2013 for the loss on the embedded conversion feature of the Senior Secured Notes, the loss on extinguishment of the Senior Secured Notes which were converted into equity in the third quarter of 2013, and the accrued interest expense on the Senior Secured Notes.
Nine Months Ended September 30, 2014 Financial Results
Revenue for the nine months ended September 30, 2014 was $610,705, compared to $510,272 for the same period in 2013, an increase of $100,433, or 20%. The increase in revenue for 2014 was due to higher sales of orthoPACE devices in 2014 in Asia/Pacific, as compared to the prior year, as well as higher sales of refurbished applicators in Europe.
Operating expenses for the nine months ended September 30, 2014 were $5,505,008, compared to $5,150,587 for the same period in 2013, an increase of $354,421, or 7%. The increase in operating expenses is primarily a result of the dermaPACE clinical study starting the more costly enrollment phase in June 2013.
Net loss for the nine months ended September 30, 2014 was $5,750,509, or ($0.12) per basic and diluted share, compared to a net loss of $10,624,454, or ($0.43) per basic and diluted share, for the same period in 2013, a decrease in the net loss of $4,873,945, or 46%. The decrease in the net loss was primarily a result of the non-cash other expenses which totaled $5,625,775 in 2013 for the loss on the embedded conversion feature of the Senior Secured Notes which were converted to equity in the third quarter of 2013, the loss on extinguishment of the Senior Secured Notes in the third quarter of 2013, and the accrued interest expense on the Senior Secured Notes. These other expenses were partially offset by increased research and development expenses in 2014 for the dermaPACE clinical study.
On September 30, 2014, the Company had cash and cash equivalents of $4,687,222 compared with $182,315 as of December 31, 2013, an increase of $4,504,907. For the nine months ended September 30, 2014 and 2013, net cash used by operating activities was $5,542,192 and $3,374,894, respectively, an increase of $2,167,298, or 64%. The increase was primarily due to the increased research and development expenses in 2014, as compared to 2013, of $741,866 for expenses associated with the dermaPACE clinical trial as a result of the clinical study starting the more costly enrollment phase in June 2013 and the reduction of accounts payable and accrued expenses in 2014 of $1,036,708. Net cash provided by financing activities for the nine months ended September 30, 2014 and 2013 was $10,071,149 and $3,636,703, respectively, which in 2014 primarily consisted of the net proceeds from the 2014 Private Placement of $8,562,500, the proceeds from sale of capital stock per the Subscription Agreement with a related party of $900,000, and the proceeds from the 18% Convertible Promissory Notes of $815,000. In 2013, net cash provided by financing activities primarily consisted of the net proceeds from the subscriptions payable for Senior Secured Notes of $1,570,000 and the net proceeds from the July 2013 public offering of $1,517,450.
The Company will host a conference call on Thursday, November 13, 2014, beginning at 10:00 AM ET to discuss the third quarter financial results and provide a business update.
Shareholders and other interested parties can participate in the conference call by dialing 877-407-9055 (U.S. and Canada) or 201-493-6743 (international).
A replay of the conference call will be available beginning two hours after its completion through November 27, 2014 by dialing 877-660-6853 (U.S. and Canada) or 201-612-7415 (international) and entering Conference ID 414704.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
(FINANCIAL TABLES FOLLOW)
|SANUWAVE HEALTH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|September 30,||December 31,|
|Cash and cash equivalents||$ 4,687,222||$ 182,315|
|Accounts receivable - trade, net of allowance for doubtful accounts of $48,044 in 2014 and $43,282 in 2013||94,954||139,736|
|TOTAL CURRENT ASSETS||5,202,444||643,077|
|PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation||8,814||13,267|
|INTANGIBLE ASSETS, at cost, less accumulated amortization||690,202||920,269|
|TOTAL ASSETS||$ 5,912,688||$ 1,588,057|
|Accounts payable||$ 402,674||$ 935,028|
|Accrued employee compensation||117,700||140,102|
|Interest payable, related parties||81,864||163,729|
|Notes payable, related parties||5,372,743||--|
|Convertible promissory note||--||147,775|
|Capital lease payable||--||3,951|
|TOTAL CURRENT LIABILITIES||6,334,199||2,343,195|
|Notes payable, related parties||--||5,372,743|
|COMMITMENTS AND CONTINGENCIES||--||--|
|STOCKHOLDERS' EQUITY (DEFICIT)|
|PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 shares authorized; 6,175 shares issued and outstanding||6||--|
|PREFERRED STOCK - UNDESIGNATED, par value $0.001, 4,993,825 shares authorized; no shares issued and outstanding||--||--|
|COMMON STOCK, par value $0.001, 150,000,000 shares authorized; 50,706,519 and 37,984,182 issued and outstanding in 2014 and 2013, respectively||50,707||37,984|
|ADDITIONAL PAID-IN CAPITAL||87,496,831||76,037,490|
|ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)||(8,503)||6,688|
|TOTAL STOCKHOLDERS' EQUITY (DEFICIT)||(421,511)||(6,127,881)|
|TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)||$ 5,912,688||$ 1,588,057|
|SANUWAVE HEALTH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS|
|Three Months Ended||Three Months Ended||Nine Months Ended||Nine Months Ended|
|September 30,||September 30,||September 30,||September 30,|
|REVENUE||$ 227,492||$ 148,421||$ 610,705||$ 510,272|
|COST OF REVENUE||68,077||29,467||149,813||109,061|
|Research and development||708,304||775,717||2,486,801||1,744,935|
|General and administrative||780,115||1,151,709||2,774,828||3,160,749|
|TOTAL OPERATING EXPENSES||1,568,935||2,008,969||5,505,008||5,150,587|
|OTHER INCOME (EXPENSE)|
|Loss on embedded conversion feature of Senior Secured Notes||--||(964,813)||--||(2,373,813)|
|Loss on extinguishment of Senior Secured Notes||--||(1,073,572)||--||(1,073,572)|
|Accretion of interest and interest expense on Senior Secured Notes||--||(421,060)||--||(2,178,390)|
|Interest expense, net||(79,955)||(88,772)||(700,085)||(256,472)|
|Gain on sale of fixed assets||--||--||--||7,500|
|Gain (loss) on foreign currency exchange||(3,430)||1,442||(6,308)||(331)|
|TOTAL OTHER INCOME (EXPENSE)||(83,385)||(2,546,775)||(706,393)||(5,875,078)|
|LOSS BEFORE INCOME TAXES||(1,492,905)||(4,436,790)||(5,750,509)||(10,624,454)|
|INCOME TAX EXPENSE||--||--||--||--|
|OTHER COMPREHENSIVE INCOME (LOSS)|
|Foreign currency translation adjustments||(10,210)||(1,829)||(15,191)||(5,804)|
|TOTAL COMPREHENSIVE LOSS||$ (1,503,115)||$ (4,438,619)||$ (5,765,700)||$ (10,630,258)|
|LOSS PER SHARE:|
|Net loss - basic and diluted||$ (0.03)||$ (0.14)||$ (0.12)||$ (0.43)|
|Weighted average shares outstanding - basic and diluted||50,706,519||31,874,479||46,258,912||24,969,972|
|SANUWAVE HEALTH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Nine Months Ended||Nine Months Ended|
|September 30,||September 30,|
|CASH FLOWS FROM OPERATING ACTIVITIES|
|Net loss||$ (5,750,509)||$ (10,624,454)|
|Adjustments to reconcile net loss to net cash used by operating activities|
|Change in allowance for doubtful accounts||4,762||352|
|Stock-based compensation - employees, directors and advisors||91,788||683,382|
|Stock issued for consulting services||743,150||751,587|
|Accrued interest on 18% Convertible Promissory Notes||7,168||--|
|Accretion of interest on warrants issued concurrent with a convertible promissory note||339,864||--|
|Loss on embedded conversion feature of Senior Secured Notes||--||2,373,813|
|Accretion of interest and accrued interest on Senior Secured Notes||--||2,178,390|
|Loss on extinguishment of Senior Secured Notes||--||1,073,572|
|Gain on sale of property and equipment||--||(7,500)|
|Changes in assets - (increase)/decrease|
|Accounts receivable - trade||40,020||21,554|
|Changes in liabilities - increase/(decrease)|
|Accrued employee compensation||(22,402)||(106,426)|
|Interest payable, related parties||(81,865)||--|
|Promissory notes - accrued interest||(21,813)||1,450|
|NET CASH USED BY OPERATING ACTIVITIES||(5,542,192)||(3,374,894)|
|CASH FLOWS FROM INVESTING ACTIVITIES|
|Sale of property and equipment||--||7,500|
|Purchase of property and equipment||(8,859)||--|
|NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES||(8,859)||7,500|
|CASH FLOWS FROM FINANCING ACTIVITIES|
|Proceeds from 2014 Private Placement, net||8,562,500||--|
|Proceeds from sale of capital stock - subscription agreement||900,000||75,000|
|Proceeds from 18% Convertible Promissory Notes||815,000||--|
|Proceeds from convertible promissory notes, net||325,000||--|
|Proceeds from employee stock option exercise||12,600||37,917|
|Proceeds from subscriptions payable for Senior Secured Notes||--||1,570,000|
|Proceeds from public offering, net||--||1,517,450|
|Proceeds from private placement||--||405,000|
|Proceeds from promissory notes||--||360,000|
|Payments of principal on convertible promissory notes||(450,000)||--|
|Payments of principal on promissory notes||(90,000)||(325,000)|
|Payments of principal on capital lease||(3,951)||(3,664)|
|NET CASH PROVIDED BY FINANCING ACTIVITIES||10,071,149||3,636,703|
|EFFECT OF EXCHANGE RATES ON CASH||(15,191)||(5,804)|
|NET INCREASE IN CASH AND CASH EQUIVALENTS||4,504,907||263,505|
|CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD||182,315||70,325|
|CASH AND CASH EQUIVALENTS, END OF PERIOD||$ 4,687,222||$ 333,830|
|Cash paid for interest, related parties||$ 325,804||$ 242,904|
CONTACT: DC Consulting, LLC 407-792-3333 firstname.lastname@example.org
Source:SANUWAVE Health, Inc.